| Recruiting | PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cerv NCT06157151 | Precigen, Inc | Phase 2 |
| Recruiting | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642 | Mayo Clinic | — |
| Active Not Recruiting | Dostarlimab and Cobolimab in Advanced Cervical Cancer NCT06238635 | Meghan Shea | Phase 2 |
| Unknown | Donafenib for Recurrent Cervical Cancer NCT05310331 | Lei Li | Phase 2 |
| Unknown | Tislelizumab and Radiotherapy for Recurrent Cervical Cancer NCT05310383 | Lei Li | Phase 2 |
| Unknown | PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer NCT05310305 | Lei Li | — |
| Unknown | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial NCT05290935 | Lei Li | Phase 2 |
| Unknown | Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma NCT04664244 | Lei Li | Phase 2 |
| Active Not Recruiting | Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer NCT04574635 | Mayo Clinic | — |
| Unknown | Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas NCT04635956 | Lei Li | Phase 2 |
| Completed | First-line Chemotherapy for Recurrent Cervical Cancer NCT04188847 | Lei Li | Phase 2 |
| Completed | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy NCT04188860 | Lei Li | Phase 2 |
| Suspended | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555 | Wake Forest University Health Sciences | — |
| Recruiting | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers NCT03968406 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer NCT03816553 | Sun Yat-sen University | Phase 2 |
| Terminated | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating P NCT03439085 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With NCT03508570 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Me NCT03452332 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer NCT03277482 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Canc NCT03345784 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer NCT02921269 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | the Re-irradiation of Recurrent Cervical Cancer by IMRT NCT03170570 | Sun Yat-sen University | N/A |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer NCT02257528 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malig NCT02578888 | Albert Einstein College of Medicine | N/A |
| Terminated | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer NCT01992861 | University of Washington | — |
| Completed | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer NCT01693783 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer NCT01266460 | Gynecologic Oncology Group | Phase 2 |
| Completed | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer NCT01267253 | Gynecologic Oncology Group | Phase 2 |
| Completed | Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Can NCT01281852 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Re NCT01266447 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Pa NCT01098630 | Gynecologic Oncology Group | — |
| Completed | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Can NCT01026792 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurre NCT00803062 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer NCT00499031 | Gynecologic Oncology Group | Phase 2 |
| Completed | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer NCT00309959 | Gynecologic Oncology Group | Phase 2 |
| Completed | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer NCT00217633 | Gynecologic Oncology Group | Phase 2 |
| Completed | Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recu NCT00064077 | Gynecologic Oncology Group | Phase 3 |
| Completed | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer NCT00057863 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer NCT00041093 | Gynecologic Oncology Group | Phase 2 |
| Completed | Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer NCT00039442 | Gynecologic Oncology Group | Phase 2 |
| Completed | Collecting Tumor Samples From Patients With Gynecological Tumors NCT00897442 | Gynecologic Oncology Group | — |